
WE CLAIM:

1. Use of a compound of Formula IIIe of the structure:



or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, in the manufacture of a medicament for the treatment of a *Flavivirus* in a host in need thereof wherein

R^7 is hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, heteroaryl, heterocyclyl, or aryl;

R^8 is hydrogen or C_{1-6}alkyl;

R^{9a} and R^{9b} are independently selected from hydrogen, C_{1-6}alkyl, and cycloalkyl;

R^{10} is hydrogen, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{3-7}cycloalkyl, heterocycloalkyl, aminoacyl, aryl, heteroaryl, aryl, or heteroaryl.

2. The use of claim 1, wherein R^7 is phenyl.

3. The use of claim 1, wherein R^7 is napthyl.

4. The use of any one of claims 1-3, wherein R^8 is hydrogen.

5. The use of any one of claim 1-3, wherein R^8 is methyl.

6. The use of any one of claims 1-5, wherein R^{9a} and R^{9b} are both C_{1-6}alkyl.

7. The use of any one of claims 1-5, wherein R^{9a} and R^{9b} are methyl.

8. The use of any one of claims 1-5, wherein R^{9a} is methyl and R^{9b} is hydrogen.

9. The use of any one of claim 1-8, wherein R^{10} is methyl, ethyl, or iso-propyl.


10. The use of claim 9, wherein R^{10} is isopropyl.

11. The use of claim 1,
wherein
R^7 is aryl;
R^8 is hydrogen;
R^{9a} and R^{9b} are independently selected from methyl and hydrogen; and
R^{10} is $C_{1\text{-}6}$alkyl.

12. The use of claim 11,
wherein
R^7 is phenyl;
R^8 is hydrogen;
R^{9a} and R^{9b} are independently selected from methyl and hydrogen; and
R^{10} is isopropyl.


13. The use of claim 1, wherein
R^7 is phenyl;
R^8 is hydrogen;
R^{9a} is methyl;
R^{9b} is hydrogen;
R^{10} is isopropyl; and
the phosphoramidate is in the L-configuration.

14. Use of a compound of the formula




or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, in the manufacture of a medicament for the treatment of a *Flavivirus* in a host in need thereof.

15. The use of claim 14, wherein an effective amount of a compound of the formula




or a pharmaceutically acceptable salt thereof is to be administered to the host.

16. The use of claim 14, wherein an effective amount of a compound




or a pharmaceutically acceptable salt thereof is to be administered to the host.

17. Use of compound of the formula




or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, in the manufacture of a medicament for the treatment of a *Flavivirus* in a host in need thereof.

18. The use of claim 17, wherein an effective amount of a compound




or a pharmaceutically acceptable salt thereof is to be administered to the host.

19. The use of claim 17, wherein an effective amount of a compound



or a pharmaceutically acceptable salt thereof is to be administered to the host.

20. Use of a compound of Formula IIIe of the structure:



or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, in the manufacture of a medicament for the treatment of Dengue fever, West Nile fever, Yellow fever, Zika virus, and Japanese encephalitis in a host in need thereof wherein

R^7 is hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, heteroaryl, heterocyclyl, or aryl;

R^8 is hydrogen or C_{1-6}alkyl;


R^{9a} and R^{9b} are independently selected from hydrogen, C_{1-6}alkyl, and cycloalkyl;

R^{10} is hydrogen, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{3-7}cycloalkyl, heterocycloalkyl, aminoacyl, aryl, heteroaryl, aryl, or heteroaryl.

21. The use of claim 20, wherein the virus is Dengue fever.


22. The use of claims 20 or 21, wherein the host is a human.

23. The use of claim 20, wherein the compound is of the formula:




or a pharmaceutically acceptable salt thereof.

24. The use of claim 23, wherein the compound is of the formula:




or a pharmaceutically acceptable salt thereof.

25. The use of claim 23, wherein the compound is of the formula:




or a pharmaceutically acceptable salt thereof.


26. The use of claim 20, wherein the compound is selected from the formula:



,



, and



or a pharmaceutically acceptable salt thereof.

27. The use of any one of claims 23-26, wherein the virus is Dengue Fever.

28. The use of claim 27, wherein the Dengue Fever is Dengue Fever 2.

29. The use of claim 27, wherein the Dengue Fever is Dengue Fever 3.


30. The use of any one of claims 23-26, wherein the virus is West Nile Fever.

31. The use of any one of claims 23-26, wherein the virus is Yellow Fever.

32. The use of any one of claims 23-26, wherein the virus is Zika virus.

33. The use of any one of claims 23-32, wherein the host is a human.

34. Use of a compound of Formula IIIe of the structure:



or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, in the manufacture of a medicament for the treatment of a *Coronaviridae* viral infection in a host in need thereof wherein

R^7 is hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, heteroaryl, heterocyclyl, or aryl;

R^8 is hydrogen or C_{1-6}alkyl;

R^{9a} and R^{9b} are independently selected from hydrogen, C_{1-6}alkyl, and cycloalkyl;

R^{10} is hydrogen, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{3-7}cycloalkyl, heterocycloalkyl, aminoacyl, aryl, heteroaryl, aryl, or heteroaryl.

35. The use of claim 34, wherein R^7 is phenyl or napthyl.

36. The use of claim 34 or 35, wherein R^8 is hydrogen.

37. The use of any one of claims 34-36, wherein R^{9a} and R^{9b} are both C_{1-6}alkyl.

38. The use of claim 37, wherein R^{9a} and R^{9b} are methyl.

39. The use of any one of claims 34-36, wherein R^{9a} is methyl and R^{9b} is hydrogen.

40. The use of any one of claim34-39, wherein R^{10} is methyl, ethyl, or iso-propyl.

41. The use of claim 40, wherein R^{10} is isopropyl.

42. The use of claim 34,

wherein

R^7 is aryl;

R^8 is hydrogen;

R^{9a} and R^{9b} are independently selected from methyl and hydrogen; and

R^{10} is $C_{1\text{-}6}$alkyl.

43. The use of claim 42,

wherein

R^7 is phenyl;

R^8 is hydrogen;

R^{9a} and R^{9b} are independently selected from methyl and hydrogen; and

R^{10} is isopropyl.

44. The use of claim 43, wherein

R^7 is phenyl;

R^8 is hydrogen;


R^{9a} is methyl;

R^{9b} is hydrogen;

R^{10} is isopropyl; and


the phosphoramidate is in the L-configuration.

45. The use of claim 34, wherein the compound is of the formula:




or a pharmaceutically acceptable salt thereof.

46. The use of claim 45, wherein the compound is of the formula:




or a pharmaceutically acceptable salt thereof.

47. The use of claim 45, wherein the compound is of the formula:




or a pharmaceutically acceptable salt thereof.


48. The use of claim 34, wherein the compound is selected from the formula:



,



, and



or a pharmaceutically acceptable salt thereof.

49. The use of any one of claims 34-48 wherein the *Coronaviridae* viral infection is a virus of the genus *Alphacoronavirus*.

50. The use of any one of claims 34-48 wherein the *Coronaviridae* viral infection is a virus of the genus *Betacoronavirus*.

51. The use of any one of claims 34-48 wherein the *Coronaviridae* viral infection is a virus of the genus *Gammacoronavirus*.

52. The use of any one of claims 34-48 wherein the *Coronaviridae* viral infection is a virus of the genus *Deltacoronavirus*.

53. The use of any one of claims 34-52, wherein the host is a human.

54. The use of any one of claims 1-53, wherein the compound is to be administered in a dosage form suitable for oral administration.

55. The use of claim 54, wherein the dosage form is a solid oral dosage form.

56. The use of claim 55, wherein the solid oral dosage form is a tablet or capsule.

57. The use of claim 54, wherein the dosage form is a liquid oral dosage form.

58. The use of claim 57, wherein the liquid oral dosage form is a solution or a suspension.

59. The use of any one of claims 1-53, wherein the compound is to be administered in a dosage form suitable for intravenous administration.

60. The use of any one of claims 1-53, wherein the compound is to be administered in a dosage form suitable for parenteral administration.